Register entry
ASTELLAS PHARMA GLOBAL DEVELOPMENT INC
- Registered sites
- 0
- Active NDC listings
- 0
- Live patents
- 22
- Countries
- 0
Exclusivity
Patents and exclusivities
22| Patent | Product | Covers | Expiry |
|---|---|---|---|
| 8772315 | MYRBETRIQmirabegron | use | Oct 2028 |
| 8772315*PED | MYRBETRIQmirabegron | use | Apr 2029 |
| 10842780 | MYRBETRIQmirabegron | product | Sept 2029 |
| 11707451 | MYRBETRIQmirabegron | use | Sept 2029 |
| 12059409 | MYRBETRIQmirabegron | product | Sept 2029 |
| 12097189 | MYRBETRIQmirabegron | use | Sept 2029 |
| 10842780*PED | MYRBETRIQmirabegron | use | Mar 2030 |
| 11707451*PED | MYRBETRIQmirabegron | use | Mar 2030 |
| 12059409*PED | MYRBETRIQmirabegron | use | Mar 2030 |
| 12097189*PED | MYRBETRIQmirabegron | use | Mar 2030 |
| 10058536 | MYRBETRIQ GRANULESmirabegron | product | Mar 2036 |
| 10058536*PED | MYRBETRIQ GRANULESmirabegron | use | Sept 2036 |
Enquiry
Common questions
- Is ASTELLAS PHARMA GLOBAL DEVELOPMENT INC FDA approved?
- ASTELLAS PHARMA GLOBAL DEVELOPMENT INC holds no registered establishment of its own; it appears here on its Orange Book patents.
Compiled from FDA establishment registrations, the openFDA NDC Directory, the Orange Book and the FDA drug shortage database. Not claimed by the company. Sources and methodology.